RT Journal Article
SR Electronic
T1 Impacts of regional climate on the COVID-19 fatality in 88 countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.13.20130013
DO 10.1101/2020.06.13.20130013
A1 Minneng Wen
A1 Liyuan Chen
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.06.13.20130013.abstract
AB The COVID-19 pandemic had led to 500000 confirmed death by June 30, 2020. We combined the number of monthly confirmed new cases and deaths with latitude, temperature, humidity, rainfall, and sunshine ultraviolet (UV) to explore the climate impacts on COVID-19 fatality in 88 countries. There was a significant decrease in overall case-fatality rate in May and June (from 8.17% to 4.99% and 3.22%). The fatality in temperate marine regions was the highest (11.13%). The fatality was 5.71% in high latitudes (≥30°) but only 3.73% in low latitudes (<30°). The fatality was 6.76% in cold regions (<20°C) but only 3.90% in hot regions (≥20°C). The fatality was 5.87% in rainy regions (≥40mm) but only 3.33% in rainless regions (<40mm). The fatality was 6.57% in cloudy regions (<50) but only 3.86% in sunny regions (≥50). Traveling to hot sunny regions without pollution is a strategy for risk reduction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding source for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There is no ethics in this article.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusion in the paper are present in the paper or the supplementary materials.